Search results
Results from the WOW.Com Content Network
[41] c-KIT- and PDGFRA-mutation negative GIST tumors are usually resistant to treatment with imatinib, [16] as is neurofibromatosis-1-associated wild-type GIST. [36] A specific subtype of PDGFRA mutation, D842V, is also insensitive to imatinib. [36] [42] Recently, in PDGFRA-mutated GIST, avapritinib has been approved by FDA. [43]
Patients in response categories 4-9 should be considered as failing to respond to treatment (disease progression). Thus, an incorrect treatment schedule or drug administration does not result in exclusion from the analysis of the response rate. Precise definitions for categories 4-9 will be protocol specific.
The prognosis for these types of tumors depends heavily on the size of the tumor and the rate of mitosis, however approximately 60 percent of GISTs are diagnosed as benign. [4] Surgery to remove the tumor is the primary treatment method, although imatinib, everolimus, and rapamycin may soon be approved as alternative treatment and management ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. [1] It is a form of xenotransplantation. PDX models are used to create an environment that allows for the continued growth of cancer after its removal from a patient.
Avapritinib, sold under the brand name Ayvakit among others, is a medication used for the treatment of advanced systemic mastocytosis and indolent systemic mastocytosis. It is also used for the treatment of tumors due to one specific rare mutation: it is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbor a platelet-derived growth ...
A BiTE linking a T cell to a tumor cell. Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, BiTEs form a link between T cells and tumor cells. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules.
Carcinoid tumors are the most common malignant tumor of the appendix, but they are most commonly associated with the small intestine, and they can also be found in the rectum and stomach. They are known to grow in the liver, but this finding is usually a manifestation of metastatic disease from a primary carcinoid occurring elsewhere in the body.